Your browser doesn't support javascript.
loading
Genetic Variants That Predispose to DNA Double-Strand Breaks in Lymphocytes From a Subset of Patients With Familial Colorectal Carcinomas.
Arora, Sanjeevani; Yan, Hong; Cho, Iltaeg; Fan, Hua-Ying; Luo, Biao; Gai, Xiaowu; Bodian, Dale L; Vockley, Joseph G; Zhou, Yan; Handorf, Elizabeth A; Egleston, Brian L; Andrake, Mark D; Nicolas, Emmanuelle; Serebriiskii, Ilya G; Yen, Timothy J; Hall, Michael J; Golemis, Erica A; Enders, Greg H.
Afiliação
  • Arora S; Cancer Biology Program, Fox Chase Cancer Center, Philadelphia, Pennsylvania; Molecular Therapeutics Program, Fox Chase Cancer Center, Philadelphia, Pennsylvania.
  • Yan H; Cancer Biology Program, Fox Chase Cancer Center, Philadelphia, Pennsylvania.
  • Cho I; Department of Biochemistry and Biophysics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania.
  • Fan HY; Department of Biochemistry and Biophysics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania.
  • Luo B; Institute for Personalized Medicine, Fox Chase Cancer Center, Philadelphia, Pennsylvania.
  • Gai X; Massachusetts Eye and Ear Infirmary, Harvard Medical School, Boston, Massachusetts.
  • Bodian DL; Inova Translational Medicine Institute, Inova Health System, Falls Church, Virginia.
  • Vockley JG; Inova Translational Medicine Institute, Inova Health System, Falls Church, Virginia.
  • Zhou Y; Biostatistics, Fox Chase Cancer Center, Philadelphia, Pennsylvania.
  • Handorf EA; Biostatistics, Fox Chase Cancer Center, Philadelphia, Pennsylvania.
  • Egleston BL; Molecular Therapeutics Program, Fox Chase Cancer Center, Philadelphia, Pennsylvania; Biostatistics, Fox Chase Cancer Center, Philadelphia, Pennsylvania.
  • Andrake MD; Molecular Therapeutics Program, Fox Chase Cancer Center, Philadelphia, Pennsylvania.
  • Nicolas E; Genomics, Fox Chase Cancer Center, Philadelphia, Pennsylvania.
  • Serebriiskii IG; Molecular Therapeutics Program, Fox Chase Cancer Center, Philadelphia, Pennsylvania; Kazan Federal University, Kazan, Russia.
  • Yen TJ; Cancer Biology Program, Fox Chase Cancer Center, Philadelphia, Pennsylvania.
  • Hall MJ; Medical Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania; Clinical Genetics, Fox Chase Cancer Center, Philadelphia, Pennsylvania.
  • Golemis EA; Molecular Therapeutics Program, Fox Chase Cancer Center, Philadelphia, Pennsylvania. Electronic address: erica.golemis@fccc.edu.
  • Enders GH; Cancer Biology Program, Fox Chase Cancer Center, Philadelphia, Pennsylvania; Medicine, Fox Chase Cancer Center, Philadelphia, Pennsylvania. Electronic address: greg.enders@fccc.edu.
Gastroenterology ; 149(7): 1872-1883.e9, 2015 Dec.
Article em En | MEDLINE | ID: mdl-26344056
ABSTRACT
BACKGROUND &

AIMS:

DNA structural lesions are prevalent in sporadic colorectal cancer. Therefore, we proposed that gene variants that predispose to DNA double-strand breaks (DSBs) would be found in patients with familial colorectal carcinomas of an undefined genetic basis (UFCRC).

METHODS:

We collected primary T cells from 25 patients with UFCRC and matched patients without colorectal cancer (controls) and assayed for DSBs. We performed exome sequence analyses of germline DNA from 20 patients with UFCRC and 5 undiagnosed patients with polyposis. The prevalence of identified variants in genes linked to DNA integrity was compared with that of individuals without a family history of cancer. The effects of representative variants found to be associated with UFCRC was confirmed in functional assays with HCT116 cells.

RESULTS:

Primary T cells from most patients with UFCRC had increased levels of the DSB marker γ(phosphorylated)histone2AX (γH2AX) after treatment with DNA damaging agents, compared with T cells from controls (P < .001). Exome sequence analysis identified a mean 1.4 rare variants per patient that were predicted to disrupt functions of genes relevant to DSBs. Controls (from public databases) had a much lower frequency of variants in the same genes (P < .001). Knockdown of representative variant genes in HCT116 CRC cells increased γH2AX. A detailed analysis of immortalized patient-derived B cells that contained variants in the Werner syndrome, RecQ helicase-like gene (WRN, encoding T705I), and excision repair cross-complementation group 6 (ERCC6, encoding N180Y) showed reduced levels of these proteins and increased DSBs, compared with B cells from controls. This phenotype was rescued by exogenous expression of WRN or ERCC6. Direct analysis of the recombinant variant proteins confirmed defective enzymatic activities.

CONCLUSIONS:

These results provide evidence that defects in suppression of DSBs underlie some cases of UFCRC; these can be identified by assays of circulating lymphocytes. We specifically associated UFCRC with variants in WRN and ERCC6 that reduce the capacity for repair of DNA DSBs. These observations could lead to a simple screening strategy for UFCRC, and provide insight into the pathogenic mechanisms of colorectal carcinogenesis.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Variação Genética / Linfócitos T / Neoplasias Colorretais / Biomarcadores Tumorais / Quebras de DNA de Cadeia Dupla Tipo de estudo: Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Aged80 Idioma: En Ano de publicação: 2015 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Variação Genética / Linfócitos T / Neoplasias Colorretais / Biomarcadores Tumorais / Quebras de DNA de Cadeia Dupla Tipo de estudo: Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Aged80 Idioma: En Ano de publicação: 2015 Tipo de documento: Article